Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.
Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.
Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.
Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.
et al., 2021, Suppressor CD4+ T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis, Gut, ISSN:0017-5749
et al., 2021, Binge-eating disorder is associated with an unfavourable body mass composition in patients with Non-alcoholic fatty liver disease, International Journal of Eating Disorders, Vol:75 Supplement 2, ISSN:0276-3478, Pages:S537-S538
et al., 2021, Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events, Journal of Hepatology, Vol:75, ISSN:0168-8278, Pages:S36-S48
et al., 2021, Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals., Lancet Gastroenterol Hepatol, Vol:6, Pages:527-528
et al., 2021, Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis, Journal of Hepatology, Vol:75, ISSN:0168-8278, Pages:177-189